Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: A systematic review

• Published in: PLoS neglected tropical diseases Vol. 17; no. 2; p. e0011022
• Main Authors: Pham, Khanh, Mertelsmann, Anna, Mages, Keith, Kingery, Justin R, Mazigo, Humphrey D, Jaka, Hyasinta, Kalokola, Fredrick, Changalucha, John M, Kapiga, Saidi, Peck, Robert N, Downs, Jennifer A
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01-02-2023; Public Library of Science (PLoS)
• Subjects: Animals; Anthelmintic agents; Anthelmintics - therapeutic use; Antiparasitic agents; Arteriosclerosis; Atherosclerosis; Biology and Life Sciences; Blood pressure; C-Reactive Protein; Cardiovascular disease; Cardiovascular Diseases; Care and treatment; Cholesterol; Clinical trials; Cohorts; Complications and side effects; Cross-Sectional Studies; Diabetes; Diabetes Mellitus; Diseases; Dyslipidemia; Eradication; Health risks; Health services; Helminthiasis; Helminthiasis - prevention & control; Helminths; High density lipoprotein; Humans; Infections; Insulin resistance; Lipid metabolism; Lipids; Management; Medicine and Health Sciences; Metabolic diseases; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - drug therapy; Nematodes; Protection; Risk factors; Secondary data analysis; Systematic review; Triglycerides; Tropical diseases; United States
• ISSN: 1935-2735; 1935-2727; 1935-2735
• DOI: 10.1371/journal.pntd.0011022

Globally, helminth infections and cardiometabolic diseases often overlap in populations and individuals. Neither the causal relationship between helminth infections and cardiometabolic diseases nor the effect of helminth eradication on cardiometabolic risk have been reviewed systematically in a large number of human and animal studies.
We conducted a systematic review assessing the reported effects of helminth infections and anthelmintic treatment on the development and/or severity of cardiometabolic diseases and risk factors. The search was limited to the most prevalent human helminths worldwide. This study followed PRISMA guidelines and was registered prospectively in PROSPERO (CRD42021228610). Searches were performed on December 10, 2020 and rerun on March 2, 2022 using Ovid MEDLINE ALL (1946 to March 2, 2022), Web of Science, Cochrane Library, Global Index Medicus, and Ovid Embase (1974 to March 2, 2022). Randomized clinical trials, cohort, cross-sectional, case-control, and animal studies were included. Two reviewers performed screening independently.
Eighty-four animal and human studies were included in the final analysis. Most studies reported on lipids (45), metabolic syndrome (38), and diabetes (30), with fewer on blood pressure (18), atherosclerotic cardiovascular disease (11), high-sensitivity C-reactive protein (hsCRP, 5), and non-atherosclerotic cardiovascular disease (4). Fifteen different helminth infections were represented. On average, helminth-infected participants had less dyslipidemia, metabolic syndrome, diabetes, and atherosclerotic cardiovascular disease. Eleven studies examined anthelmintic treatment, of which 9 (82%) reported post-treatment increases in dyslipidemia, metabolic syndrome, and diabetes or glucose levels. Results from animal and human studies were generally consistent. No consistent effects of helminth infections on blood pressure, hsCRP, or cardiac function were reported except some trends towards association of schistosome infection with lower blood pressure. The vast majority of evidence linking helminth infections to lower cardiometabolic diseases was reported in those with schistosome infections.
Helminth infections may offer protection against dyslipidemia, metabolic syndrome, diabetes, and atherosclerotic cardiovascular disease. This protection may lessen after anthelmintic treatment. Our findings highlight the need for mechanistic trials to determine the pathways linking helminth infections with cardiometabolic diseases. Such studies could have implications for helminth eradication campaigns and could generate new strategies to address the global challenge of cardiometabolic diseases.